BioCentury
ARTICLE | Financial News

Atlas backs newco Avrobio

February 19, 2016 1:51 AM UTC

Avrobio Inc. (Cambridge, Mass.) said it secured an undisclosed amount of seed financing from Atlas Venture and licensed two cell therapy candidates from the University Health Network (Toronto, Ontario) to treat acute myelogenous leukemia (AML) and Fabry's disease.

The newco said it expects to begin Phase I studies of both candidates by mid-2016. The AML therapy, AVR-01, contains autologous T cells modified ex vivo to express IL-12. The Fabry's candidate, AVR-02, contains autologous CD34+ hematopoietic stem cells modified to express alpha-galactosidase A. ...